| Title: |
Siglec-8 as a Biomarker for Predicting Anti-IL-5 Response in Severe Asthma |
| Authors: |
Lee, Y; Kim, H; Lee, CE; Lee, BJ; Kim, MH; Park, SY; Kim, BK; Kim, SH; Park, HK; Lee, T; Shim, JS; Park, CS; Kwon, JW; Kim, S; Nam, YH; Yang, MS; Jung, JW; Kim, TB |
| Contributors: |
107733; Lee, Y |
| Publication Year: |
2025 |
| Subject Terms: |
Asthma; biological therapy; biomarkers; eosinophils; IL-5; immunologic; receptors; treatment |
| Description: |
PURPOSE: Biologic therapies have revolutionized the management of severe asthma (SA), yet the variability in patient responses necessitates identification/verification of predictive biomarkers. Siglec-8, a sialic acid-binding immunoglobulin-like lectin 8 selectively that is expressed on eosinophils, could serve as a biomarker for predicting responsiveness to biologics in patients with SA. It is necessary to evaluate the predictive value of baseline serum Siglec-8 levels compared to other parameters, including blood eosinophil counts, in determining clinical responses to anti-interleukin 5 (IL-5) therapies in patients with SA. METHODS: This study included 68 patients with SA from the Precision Medicine Intervention in Severe Asthma study, who had initiated anti-IL-5 therapies and whose baseline serum Siglec-8 levels were measured. Clinical outcomes were assessed at 6 and 12 months following treatment. Excellent responders were defined as patients with zero exacerbations during follow-up. Multivariable logistic regression and receiver operating characteristic curve analyses were performed to compare the predictive performance of serum Siglec-8 levels versus that of other parameters. RESULTS: Data from 29 patients treated with mepolizumab and 39 patients treated with reslizumab were analyzed. Baseline serum Siglec-8 levels showed a trend toward better diagnostic performance compared to blood eosinophil counts for predicting 6- and 12-month clinical responses (area under the curve, 0.931 vs. 0.836; P = 0.08 for 6-month responders; and 0.811 vs. 0.628, P = 0.05 for 12-month excellent responders). Additionally, the ratio of serum Siglec-8 levels to blood eosinophil counts significantly increased after 6 months of anti-IL-5 therapy (P < 0.001). CONCLUSIONS: Baseline serum Siglec-8 levels showed a trend toward better predictive performance than other parameters for predicting 6- and 12-month responses to anti-IL-5 therapies in patients with SA. These findings suggest that Siglec-8 may have the potential as a ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
J020927355; http://repository.ajou.ac.kr/handle/201003/34869; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12683740 |
| DOI: |
10.4168/aair.2025.17.6.742 |
| Availability: |
http://repository.ajou.ac.kr/handle/201003/34869; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12683740; https://doi.org/10.4168/aair.2025.17.6.742 |
| Accession Number: |
edsbas.5C9B9E89 |
| Database: |
BASE |